TruSight Cancer Sequencing Panel Kit is a library preparation kit for rapid sequencing and screening of cancer-related genes on Illumina’s Next Generation Sequencing (NGS) system.
Illumina
Reagents
Target to 94 genes, >1700 exons are associated with common cancers such as breast cancer, colorectal cancer and rare cancers, targeted area size is 255 kb, 284 SNPs
Developed with cancer genomics experts in collaboration, oligos ready-to-use, pre-engineered oligos allow researchers to sequence a wide range of genes and single nucleotide polymorphisms (SNPs) in advance. this is related to cancer predisposition
TruSight Cancer Sequencing Panel Kit is a library preparation kit for rapid sequencing and screening of cancer-related genes on Illumina’s Next Generation Sequencing (NGS) system.
TECHNOLOGY | Next generation gene sequencing |
---|---|
EXPERIMENT TIME | 1.5 H |
INPUT SAMPLE | 50 ng |
TARGET GENE | 94 genes, >1700 exons are associated with common cancers such as breast cancer, colorectal cancer and rare cancers, targeted area size is 255 kb, 284 SNPs |
TYPE SAMPLE | Low concentration sample |
COMPATIBLE AUXILIARY KIT | TruSight Rapid Capture Kits |
PROBE | Snippet Quantity is about 4000, each segment size is 80 mer |
COMPATIBLE NGS SYSTEM | MiniSeq, MiSeq, MiSeqDx in Reseach Mode, NextSeq 550 |
% EXONS COVERED | > 95% |
MINIMUM COVERAGE | 20× |
DETECTED VARIANT TYPE | Changes in Stem Cell Lineage |
Supplier | Illumina |
---|---|
Application | Ung thư (oncology) |
SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.
SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.
BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test
BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.
Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time
The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.
Model: NextSeq 1000
Manufacturer: Illumina
Origin: Singapore/United States
Launching year: 01/2020
DxFLEX is a new clinical flow cytometry platform derived from the successful CytoFLEX. The advanced sensitivity and intuitive software DxFLEX makes flow cytometry routine for both novice and expert flow cytometry technicians and promotes standardization. Functionality in the autoloader facilitates accurate results and sample tracking.
Model: iSeq 100
Manufacturer: Illumina/USA
Illumina’s smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
– Fast data generation: Suitable for small projects, on a dedicated device, low throughput with fast turnaround times
– Convenient operation: Control the sequencing process from start to finish and ensure independent sequencing instead of outsourcing.
TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants